aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2026)
aTYR PHARMA's (ATYR) quarterly Income from Non-Controlling Interests came in at -$1000.0 in Q2 2026, little changed on a YoY basis from -$1000.0 in Q2 2025, and little changed quarter-over-quarter from -$1000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Income from Non-Controlling Interests for 7 consecutive years, with -$1000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Non-Controlling Interests changed 0.0% year-over-year to -$1000.0; the trailing twelve-month figure through Jun 2026 stood at -$5000.0 (changed 0.0% YoY), and the FY2025 full-year result was -$5000.0, down 600.0% from the prior year.
- Income from Non-Controlling Interests held at -$1000.0 in Q2 2026 per ATYR's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $4000.0 in Q1 2024 and bottomed at -$4000.0 in Q2 2023.
- Historically, Income from Non-Controlling Interests has averaged -$1117.6 across 5 years, with a median of -$1000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Income from Non-Controlling Interests slumped 300.0% in 2023, then jumped 500.0% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at -$2000.0 in 2022, then soared by 50.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then changed by 0.0% to -$1000.0 in 2025, then changed by 0.0% to -$1000.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$1000.0, -$1000.0, and -$1000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -100.77 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | -1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | -1,000.00 |
| Dec 31, 2022 | -2,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | -1,000.00 |
| Mar 31, 2022 | -1,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -1,000.00 |